Crinetics Pharmaceuticals, Inc. (CRNX)
| Market Cap | 467.83M |
| Revenue (ttm) | 392,000 |
| Net Income (ttm) | -66.72M |
| Shares Out | 32.89M |
| EPS (ttm) | -2.36 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 19 |
| Last Price | $15.09 |
| Previous Close | $14.21 |
| Change ($) | 0.88 |
| Change (%) | 6.19% |
| Day's Open | 14.52 |
| Day's Range | 14.53 - 15.10 |
| Day's Volume | 352,362 |
| 52-Week Range | 11.52 - 24.18 |
- Paltusotine planned to advance to a pivotal Phase 3 trial in acromegaly in H1 2021 -
SAN DIEGO, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals (Nasdaq: CRNX), today announced that company management will participate in the following conferences in the month of Dec...
SAN DIEGO, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization...
Webinar Being Held on Friday, November 20th @ 11:00 am Eastern Time Webinar Being Held on Friday, November 20th @ 11:00 am Eastern Time
Crinetics Pharmaceuticals (CRNX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Crinetics Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Corporate Update
Reported positive topline results for the ACROBAT Edge and Evolve Phase 2 trial s of oral paltusotine for the treatment of acromegaly
ACROBAT Edge Results Showed Maintenance of IGF-1 Suppression with Paltusotine After Switching from Depot Somatostatin Receptor Ligand Monotherapy
SAN DIEGO, Sept. 21, 2020 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercializat...
SAN DIEGO, Sept. 04, 2020 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercializat...
SAN DIEGO, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals (Nasdaq: CRNX), today announced that management will participate in the following conferences in the month of Septembe...
SAN DIEGO, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercializat...
Crinetics Pharmaceuticals (CRNX) is a clinical stage company focused on in house synthesis of novel molecules for rare endocrine diseases.
Paltusotine received Orphan Drug Designation for the treatment of acromegaly
SAN DIEGO, July 08, 2020 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercializati...
As of late, it has definitely been a great time to be an investor in Crinetics Pharmaceuticals, Inc. (CRNX).
28 patients have completed the open-label Edge trial measuring IGF-1 levels after 13 weeks of treatment when patients with acromegaly were switched to once daily oral paltusotine from commerci...
SAN DIEGO, May 27, 2020 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercializatio...
Crinetics Pharmaceuticals (CRNX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Crinetics Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Corporate Update
Reported positive interim results for the ACROBAT Edge Phase 2 trial of oral paltusotine in the treatment of acromegaly
SAN DIEGO, April 17, 2020 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercializat...
Crinetics Pharmaceuticals, Inc. (CRNX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects.
SAN DIEGO, April 15, 2020 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercializat...
SAN DIEGO, April 14, 2020 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercializat...
SAN DIEGO, April 06, 2020 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercializa...
The coronavirus induced sell-off has created a number of attractive buying opportunities.
Crinetics Pharmaceuticals, Inc. (CRNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.
These relative newcomers to the landscape of publicly-traded biotech stocks could be big winners for early shareholders.
Crinetics Pharmaceuticals, Inc. (CRNX) delivered earnings and revenue surprises of -11.11% and 51.65%, respectively, for the quarter ended September 2019.
Crinetics Pharmaceuticals, Inc. (CRNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.
SAN DIEGO, Sept. 25, 2019 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercializat...
Crinetics Pharmaceuticals (CRNX) has witnessed a significant price decline in the past four weeks, and is seeing negative earnings estimate revisions as well.
SAN DIEGO, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercializat...
Crinetics Pharmaceuticals, Inc. (CRNX) delivered earnings and revenue surprises of -13.33% and -100.00%, respectively, for the quarter ended June 2019.
About CRNX
Crinetics Pharmaceuticals, a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 biased agonist, which is in Phase I clinical trials used for the treatment of acromegaly and neuroendocrine tumors. The company is also developing CRN01941, an oral selective nonpeptide sst2 biased agonist designed for the treatment of neuroendoc... [Read more...]
| Industry Biotechnology | IPO Date Jul 18, 2018 |
| CEO R. Scott Struthers | Employees 68 |
| Stock Exchange NASDAQ | Ticker Symbol CRNX |
Financial Performance
In 2019, CRNX's revenue was $1.19 million, a decrease of -50.86% compared to the previous year's $2.43 million. Losses were -$50.42 million, 86.0% more than in 2018.
Analyst Forecasts
According to 5 analysts, the average rating for CRNX stock is "Buy." The 12-month stock price forecast is 33.60, which is an increase of 122.66% from the latest price.